|View printer-friendly version|
|Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research|
-Funds to support results-driven research and community projects engaged in HIV cure activities-
“We know from decades of work addressing the issue of HIV/AIDS that
there is no one-size-fits-all solution. Through partnerships with
dedicated and results-driven organizations – such as the worthy
recipients of our grant funding – our goal is to help in the discovery
and development of a safe and effective cure,” said
The following institutions and corresponding projects will receive funding to complete their research over the next three years (Institution/Principal Investigator/Project Name):
The HIV cure grants program, initially announced in
For nearly 30 years, Gilead has focused on the development of antiretroviral therapy to treat HIV/AIDS, helping transform HIV infection from a fatal and debilitating disease into a chronic, manageable condition. In further efforts to end the HIV epidemic, Gilead is conducting early-stage clinical research to identify novel agents and strategies that could play a role in eradicating HIV infection in the body.
In addition to the funding of these grants, Gilead was recently announced as one of the foremost corporate providers of philanthropic support to address HIV/AIDS by the Funders Concerned About AIDS (FCAA) organization.
For more information on
Gilead Sciences, Inc.
Minimum 20 minute delay